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The efficacy and tolerance of disopyramide and mexiletine 
used alone and in combination were studied in 21 patients 
with frequent (230/h) ventricular premature complexes. 
Ambulatory electrocardiographic monitoring was per- 
formed at baseline and during therapy with disopyramide 
alone, mexiletine alone and a combination of disopyramide 
and mexiletine. During single drug therapy, the dose of 
disopyramide was 602 + 152 mglday and that of mexiletine 
was 738 + 144 mg/day. During combination therapy with 
smaller doses of disopyramide (524 + 134 mg/day) and 
mexiletine (652 f 146 mg/day), no patient had side effects. 
At baseline before therapy, the mean number of ventricular 
premature complexes per hour, was 608 k 757, of couplets 
per hour was 22.4 + 45.8 and of episodes of nonsustained 
ventricular tachycardiaQ4 h was 219.7 + 758.2. The mean 
number of ventricular premature complexes per hour was 
reduced to 156 -C 217 with disopyramide alone, 188 f 298 
with mexiletine alone and 76 f 144 with combination 
therapy (p < 0.05 for combination therapy versus disopyra- 
mide or mexiletine alone; p=NS for disopyramide versus 
mexiletine). 
Individually, an effective regimen (>83% reduction in 
ventricular premature complexes and abolition of non- 
sustained ventricular tachycardia) was found in 5 (24%) of 
21 patients during therapy with disopyramide alone, in 3 
(14%) receiving mexiletine alone and in 13 (62%) receiving 
combination therapy (p < 0.05 for combination therapy 
versus disopyramide or mexiletine; p = NS for disopyra- 
mide versus mexiletine). 
Thus, the antiarrhythmic effects of disopyramide and 
mexiletine are additive. A combination of disopyramide 
and mexiletine in smaller and well tolerated doses may 
avoid dose-related side effects and is more effective than 
either drug used alone at higher doses. Therefore, when 
disopyramide or mexiletine is ineffective because dose- 
related side effects limit the maximal tolerated dose, com- 
bination therapy in smaller and more tolerable doses may 
avoid side effects and may be more effective than treatment 
with either drug alone at the maximal tolerated dose. 
(J Am Co11 Cardiol1989;13:659-#) 
Disopyramide is a class 1A antiarrhythmic agent (1) that is 
effective in the management of ventricular and supraventric- 
ular arrhythmias. Its efficacy, like that of other antiarrhyth- 
mic agents, is often limited by dose-related side effects such 
as aggravation of congestive heart failure in susceptible 
patients and symptoms caused by anticholinergic effects (2- 
5). Mexiletine, a class 1B antiarrhythmic agent, is effective 
in the management of ventricular arrhythmias. Its efficacy is 
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also limited by frequent dose-related side effects (6-S). 
Because the side effects of disopyramide differ from those of 
mexiletine, a combination of the two drugs in smaller and 
more tolerable doses may render additive antiarrhythmic 
effects without additive dose-related side effects. This hy- 
pothesis was studied in 21 patients with ventricular arrhyth- 
mias . 
Methods 
Study design. All patients had frequent @30/h) ventricu- 
lar premature complexes and were referred to the arrhyth- 
mia service of our medical center for recurrent sustained 
ventricular tachycardia (15 patients) or symptomatic venttic- 
ular arrhythmia (6 patients). All patients with sustained 
ventricular tachycardia were undergoing serial drug trials by 
invasive and noninvasive methods. No patient had previous 
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Table 1. Patient Information and Dosage of Drugs During Each Treatment 
Dose (mg/day) 
Patient No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
I1 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Mean k SD 
Age (YIY 
Gender 
74/M 
87/M 
66/M 
60/M 
78/M 
53/M 
SO/M 
45/M 
62lM 
49/M 
40/F 
59/M 
64/M 
67/M 
68/M 
77/M 
61/F 
59/M 
61/M 
50/M 
33/M 
60+ 13 
Diagnosis Arrhythmia 
CAD VT 
CAD NSVT 
CAD NSVT 
CAD VT 
CAD VT 
CAD VT 
CAD VT 
DC VT 
CAD VT 
CAD NSVT 
DC NSVT 
CAD VT 
CAD VT 
CAD VT 
CAD VT 
CAD VT 
DC VT 
CAD VT 
DC NSVT 
CAD NSVT 
ARVD VT 
Single Drug Rx Combination Rx 
Dis Mex Dis Mex 
600 800 400 600 
600 800 600 600 
600 600 600 600 
800 800 400 600 
800 800 600 800 
400 800 400 800 
600 1,000 600 1,000 
800 800 800 800 
600 600 600 600 
400 450 400 450 
400 600 400 450 
800 600 600 600 
600 600 600 600 
800 1,000 800 1,000 
400 800 400 600 
400 600 400 600 
600 800 600 600 
800 600 600 600 
400 900 400 600 
600 750 400 600 
600 800 400 600 
602 ? 152 738 ? 144 524 2 134 652 * 146 
ARVD = arrhythmogenic right ventricular dysplasia; CAD = coronary artery disease; DC = dilated cardiomyopathy; Dis = disopyramide; F = female; 
M = male; Mex = mexiletine; NSVT = nonsustained ventricular tachycardia; Rx = treatment; SD = standard deviation; VT = ventricular tachycardia. 
exposure to amiodarone therapy. Patients with a history of 
therapeutic failure with one of the study drugs were not 
excluded from the study. 
Clinical characteristics of the 21 patients are summarized 
in Table 1. There were 19 men and 2 women, aged 60 ? 13 
years. Sixteen patients had coronary artery disease, four had 
dilated cardiomyopathy and one patient had arrhythmogenic 
right ventricular dysplasia. No patient had uncompensated 
congestive heart failure at the time of entry into the study. 
Patients with a history of allergic reaction to either study 
drug were excluded from the study as were patients with a 
history of congestive heart failure associated with New York 
Heart Association functional class III or IV and patients 
with a left ventricular ejection fraction < 20% as determined 
by radionuclide angiography. The mean (5 SD) left ventric- 
ular ejection fraction was 37 + 14%. A baseline 24 h 
ambulatory electrocardiogram (ECG) was recorded in all 
patients at least five half-lives after all antiarrhythmic drugs 
were discontinued. 
Protocol. During single drug therapy with disopyramide 
and mexiletine, the initial dose of disopyramide (600 to 800 
mg/day given every 6 h in equally divided doses) and 
mexiletine (600 to 800 mg/day given every 6 to 8 h in equally 
divided doses) was adjusted to the maximal tolerated dosage 
(800 mg/day for disopyramide and 1,000 mg/day for mexile- 
tine) without side effects. To alleviate side effects, mexile- 
tine was given with a snack. Some patients received pyri- 
dostigmine during disopyramide therapy to alleviate 
anticholinergic side effects (5). To ensure steady state blood 
levels during recording, a 24 h ambulatory ECG was not 
started until the patient had received disopyramide at the 
maximal tolerated dosage for at least five doses, and mexi- 
letine at the maximal tolerated dosage for at least 2 days. 
During combination therapy with disopyramide and mexile- 
tine, many patients received less of each drug (and none 
received more) than they received during single drug ther- 
apy. The dose adjustments during combination therapy were 
largely empiric and determined by the investigators on the 
basis of side effects, patient body weight and frequency of 
ventricular premature complexes noted on the telemetry unit 
monitors. After combination therapy had been established 
for at least 2 days, another 24 h ambulatory ECG was 
recorded. Twelve lead ECGs were obtained during single 
drug and combination therapy. 
Ambulatory ECG. Continuous 24 h ambulatory ECGs 
were recorded on an Avionics 445 two channel recorder. 
Analysis of the tape was performed on a computerized 
Cardio Data System scanner. The total numbers of ventric- 
ular premature complexes, couplets and episodes of ventric- 
ular tachycardia (three or more ventricular premature com- 
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Table 2. Results of Ambulatory Electrocardiography 
Ventricular Premature Complexes/h 
Patient No. Baseline Dis Mex Combination 
I 38 3 (8%) 15 (40%) 0.2 (0.5%) 
2 222 0 (0%) I (0.5%) 0 (0%) 
3 39 21 (54%) IO (26%) I4 (36%) 
4 318 130 (41%) 25 (8%) 124 (39%) 
5 337 290 186%) 200 (59%) lc!%) 
6 2,212 13 (0.6%) I4 (0.6%) 0.7 (0.03%) 
7 102 62 (61%) 42 (41%) 6 (5%) 
8 2.395 142 (6%) 654 (27%) 75 (3%) 
9 325 176 (54%:) 39 (I?%,) 100 (31%) 
IO 216 61 (28%) 60 (28%) 54 (25%) 
II I .788 335 (19%) 141 (8%) 30 (2%) 
I2 1,119 85 (8%) 49 (4%) 38 (3%) 
I3 43 24 (56%) 591 (1374%) 21 (49%) 
I4 71 9.1 (13%) 104 (146%) 0.1 (0.1%;) 
15 32 2.1 (6%) 26 (81%) 2 (6%) 
16 411 354 (86%) I23 (30%) 457 (111%) 
17 502 732 (146%) 230 (46%) 0.1 (0.03%) 
I8 58 14 (25%) 25 (43%) 0.1 (0.2%) 
I9 963 645 (67%) 509 (53%) 145 t 15%) 
20 1,275 750 (59%) 1.120 (88%) 518 (41%) 
21 197 3.7 (2%) 2 (1%) 0 (0%) 
Mean ‘- SD 608 2 757 156 + 127 188 ? 298 76 ri- 144 
Combination = combination therapy; SD = standard deviation. Numbers in parentheses are percent of baseline 
value in each patient. 
plexes at a rate >lOO beats/min) was displayed by the 
scanner. The accuracy of this system has been published 
elsewhere (9). The mean number of ventricular premature 
complexes or couplets/h was calculated by dividing the total 
number of ventricular premature complexes or couplets by 
the number of hours of recording which was ~16 h in all 
patients during each therapy. The results were verified by 
one of us. 
Statistical methods. The mean value 2 SD was used as 
the index of dispersion of observed values. One-way analy- 
sis of variance (ANOVA), Kruskal-Wallis test or Fisher’s 
exact test was used to compare appropriate variables be- 
tween groups. A two-tailed probability (p) value of co.05 
was considered significant. 
Results 
Antiarrhythmic therapy (Table 1). During single drug 
therapy, the dosage of disopyramide was 602 +- 152 mglday 
and that of mexiletine was 738 -f. 144 mg/day. The mean 
dosage of disopyramide during combination therapy was 524 
t 134 mg/day, which was significantly less than that during 
treatment with disopyramide alone (p < 0.01). Six of the 21 
patients received a lower and none received a higher dosage 
of disopyramide during combination therapy than that re- 
ceived during single drug therapy. The mean dosage of 
mexiletine during combination therapy of 652 2 146 mg/day 
was significantly less than that during treatment with mexi- 
letine alone (p < 0.01 versus single drug therapy). Nine of 
the 21 patients received lower and none received a higher 
dosage of mexiletine during combination therapy than that 
received during single drug therapy. While receiving combi- 
nation treatment no patient had side effects attributable to 
either disopyramide or mexiletine or had worsening of 
congestive heart failure evidenced by dyspnea, a new third 
heart sound or increased respiratory rales. 
Ambulatory ECG: group responses (Tables 2 to 4). At 
baseline study before therapy, the mean number of ventric- 
ular premature complexes/h was 608 f 757, of couplets/h 
was 22.4 t 45.8 and of episodes of nonsustained ventricular 
tachycardia/24 h was 219.7 +- 758.2. The mean number of 
ventricular premature complexes/h was 156 rt 217 with 
disopyramide alone, 188 2 298 with mexiletine alone and 76 
+- 144 with combination therapy (p < 0.05 for disopyramide 
versus combination; p < 0.025 for mexiletine versus combi- 
nation; p = NS for disopyramide versus mexiletine). The 
mean number of couplets/h was 6.9 2 21.0 with disopyra- 
mide alone, 4.6 ? 13.8 with mexiletine alone and 0.3 +- 0.5 
with combination therapy (p = NS for combination versus 
disopyramide or mexiletine; disopyramide versus mexile- 
tine). The number of episodes of nonsustained ventricular 
tachycardia was 16.0 -t 44.9 with disopyramide alone, 12.7 
? 49.2 with mexiletine alone and 0.14 IT 0.48 with combina- 
tion therapy (p < 0.05 for disopyramide versus combination; 
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Table 3. Results of Ambulatory Electrocardiography 
Couplets/h 
Patient No. Baseline Dis Mex Combination 
1 0.05 0.09 0.19 0 
2 6.07 0 0 0 
3 0.33 0 0 0 
4 11.5 0.09 0.14 0.09 
5 15.9 0.72 3.75 0 
6 37 0.05 0.06 0.05 
7 7.26 0.23 0 0 
8 30.6 1.8 61 1.6 
9 11.42 1.4 0.47 0.64 
10 2.5 0.26 0.26 0.23 
11 210 93 3.3 1.16 
12 61 1.94 0.1 0.11 
13 3.29 0.1 2.03 0.52 
14 1.41 0.04 0.12 0 
15 0.94 0 0.19 0 
16 12.9 4.22 2.17 1.35 
17 3.31 0 0.17 0 
18 0.22 0.06 0.31 0 
19 30.95 10.2 22.0 0.51 
20 0.06 23.2 0.14 0.1 
21 22.7 0 0 0 
Mean + SD 22.4 k 45.8 6.9 r 21.0 4.6 ? 13.8 0.3 2 0.5 
Abbreviations as in Table 2. Abbreviations as in Table 2. 
p < 0.01 for mexiletine versus combination; p = NS for 
disopyramide versus mexiletine). 
Ambulatory ECG: individual responses (Tables 2 to 4). A 
significant (X33%) reduction in ventricular premature com- 
plexes (10) was noted in 8 of the 21 patients receiving 
disopyramide alone, 7 of 21 patients receiving mexiletine 
alone and 14 of 21 patients receiving combination therapy 
(p=NS for disopyramide versus combination, mexiletine 
versus combination and disopyramide versus mexiletine). 
Among 16 patients who had nonsustained ventricular tachy- 
cardia at baseline study before therapy, abolition of non- 
sustained ventricular tachycardia (11) was noted in 9 patients 
during disopyramide therapy, 7 patients during mexiletine 
therapy and 15 patients during the combination therapy (p < 
0.05 for disopyramide versus combination; p < 0.01 for 
mexiletine versus combination; p = NS for disopyramide 
versus mexiletine). An effective regimen defined as a >83% 
reduction in ventricular premature complexes and abolition 
of nonsustained ventricular tachycardia (10-12) was found in 
5 patients (24%) receiving disopyramide alone, 3 (14%) 
taking mexiletine alone and 13 (62%) receiving combination 
treatment (p < 0.05 for disopyramide versus combination; p 
< 0.01 for mexiletine versus combination; p = NS for 
mexiletine versus disopyramide). 
Twelve lead ECG (Table 5). Compared with baseline 
values, significant (p < 0.005) prolongation of the QTc 
interval (corrected QT interval by the Bazett formula) (13) 
was noted during disopyramide and combination therapy. 
Table 4. Results of Ambulatory Electrocardiography 
Episodes of Ventricular Tachvcardiai24 h 
Patient No. Baseline Dis Mex Combination 
1 3 1 0 0 
2 11 0 0 0 
3 0 0 0 0 
4 38 0 0 0 
5 15 0 7 0 
6 88 0 1 0 
7 1 0 1 0 
8 525 116 229 1 
9 20 5 1 0 
10 0 0 0 0 
11 3,474 172 6 0 
12 394 4 1 0 
13 0 0 1 2 
14 1 0 0 0 
15 8 0 0 0 
16 14 0 0 0 
17 I 0 3 0 
18 2 2 0 0 
19 19 19 17 0 
20 0 0 0 0 
21 0 0 0 0 
Mean t SD 219.7 t 758.2 16.0 t 44.9 12.7 ? 49.2 0.14 k 0.48 
The prolongation of the QRS complex observed during 
disopyramide and combination treatment was statistically 
insignificant. During mexiletine therapy, no significant 
changes in duration of the QRS complex and QTc interval 
were noted. The QTc interval during combination therapy 
was significantly (p < 0.01) shorter than that during disopy- 
ramide alone. 
Discussion 
This study suggests that in patients with ventricular 
arrhythmias 1) the antiarrhythmic effects of disopyramide 
and mexiletine are additive, and 2) a combination of disopy- 
ramide and mexiletine in smaller and well tolerated doses 
may avoid dose-related side effects and is more effective 
than either drug used alone at higher doses. Therefore, when 
disopyramide or mexiletine is ineffective because dose- 
related side effects limit the maximal tolerated dosage, 
combination therapy with both drugs in smaller and more 
Table 5. Electrocardiographic Intervals (s) in 21 Patients 
PR QRS QTc 
Baseline 0.18 t 0.02 0.106 + 0.020 0.423 2 0.032 
Disopyramide 0.18 k 0.03 0.127 2 0.027 0.479 + 0.023 
Mexiletine 0.17 2 0.01 0.108 + 0.027 0.416 + 0.025 
Combination 0.18 2 0.02 0.125 ” 0.024 0.453 + 0.021 
Combination = combination therapy 
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tolerable dosages may be more effective than either drug 
alone at maximal tolerated dosages. 
Ambulatory ECG monitoring and efficacy criteria. A 24 h 
ambulatory ECG was used to assess the antiarrhythmic 
efficacy of single drug and combination therapy in this study 
(9-12,14-l@. Because of day to day variations in the fre- 
quency of ventricular premature complexes in individual 
patients (lo), a therapy was considered effective in individ- 
ual patients when a >83% reduction in the number of 
ventricular premature complexes and abolition of non- 
sustained ventricular tachycardia were noted (10-12). In 
assessing antiarrhythmic agents in groups of patients, how- 
ever, the spontaneous variability in individual patients be- 
comes less important, and less dramatic reductions in ven- 
tricular ectopic activity are considered significant (14). The 
combination therapy was more effective than single drug 
therapy with disopyramide or mexiletine when group re- 
sponses as well as individual responses were considered. 
Single drug therapy. The results during single drug ther- 
apy suggest that our study patients and methods are not 
significantly different from those of other studies. In our 
study, a significant (X33%) reduction in ventricular prema- 
ture complexes was noted in 38% of patients during disopy- 
ramide therapy. Others (3) have reported similar efficacy 
rates with disopyramide therapy. Many investigators have 
reported that the efficacy of disopyramide is limited because 
dose-related anticholinergic side effects limit the maximal 
tolerated dose of disopyramide. The response of our patients 
to mexiletine is similar to that reported by others (19). The 
efficacy of mexiletine is also limited because of dose-related 
extracardiac side effects in many patients. Other investiga- 
tors (20) used shorter dosing intervals (every 6 h rather than 
every 8 h, as we did in some patients) to lessen the 
dose-related side effects of mexiletine. By giving the same 
total daily dosage of a drug in smaller and more frequent 
doses, one can avoid the sharp increase in serum drug 
concentration and dose-related side effects. 
Combination therapy. The combination of different anti- 
arrhythmic agents has been reported on by several investi- 
gators (9,16,2&22). Duff et al. (20) reported enhanced effi- 
cacy and a reduction in dose-related side effects of 
mexiletine when combined with quinidine. They reported 
that the addition of mexiletine to quinidine shortened the 
quinidine-induced increase in the QTc interval. In our study, 
the QTc interval during combination therapy was signifi- 
cantly shorter than that during disopyramide therapy alone. 
However, because the dosage of disopyramide was lower 
during combination therapy, one cannot determine from our 
study if mexiletine has any influence on the disopyramide- 
induced increase in the QTc interval. 
Six patients in our study received a smaller dosage of 
disopyramide and nine a smaller dosage of mexiletine during 
combination than during single drug therapy, and no patient 
had signs of worsening congestive heart failure. However, 
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therapy with disopyramide should be used with caution in 
patients with poor ventricular function. 
Clinical implications. A significant number of patients 
develop dose-related side effects from disopyramide or me- 
xiletine administered in doses that achieve plasma levels 
adequate for arrhythmia suppression (5,8). When the dose of 
the drug is reduced, the arrhythmias often recur. Our study 
suggests that a combination of smaller and well tolerated 
dosages of mexiletine and disopyramide may be useful in 
such situations. The combination of the two agents in 
smaller doses, although they may be subtherapeutic when 
used individually, may render therapeutic effects. 
Our study group involved patients referred to a tertiary 
arrhythmia center. The results may be different in other 
groups of patients. Our study included acute drug testing 
with use of 24 h ambulatory ECG monitoring. Long-term 
follow-up studies will be necessary to determine the long- 
term effects of the combination therapy with regard to 
tolerance and efficacy in preventing malignant arrhythmias. 
I 
2 
3 
4 
5 
6 
7 
8 
9 
IO 
II 
I2 
I3 
14 
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